Liraglutide not only blocks insulin receptor and synaptic loss in the brain but also reverses memory impairment induced by AD-associated Aβ oligomers, suggesting that GLP-1R activation may be used to protect brain insulin receptors and synapses in AD (Batista et al., 2018). Here, GLP1R is linked to Alzheimer disease.